Integra LifeSciences to acquire Acclarent for $280M
Integra LifeSciences entered a definitive agreement to acquire Acclarent from Ethicon (Johnson & Johnson) for $275 million in cash at closing plus up to $5 million upon regulatory milestones. Acclarent is an ENT device company headquartered in Irvine, California.
Productsballoon technologies for sinus dilationeustachian tube dilationsurgical navigation systems
“This acquisition presents Integra with a rare opportunity to become a key player in the ENT segment.”investor.integralife.com
- 3 sources
- investor.integralife.comIntegra LifeSciences Announces Definitive Agreement to Acquire Acclarent® | Integra LifeSciences Holdings CorporationDec 13, 2023
- morganlewis.comMorgan Lewis Represents Integra LifeSciences in Acquisition of Acclarent from Johnson & Johnson – NewsDec 13, 2023
- vcbeathealth.comIntegra Lifesciences to Acquire Johnson & Johnson's ENT Subsidiary Acclarent for $275 Million-VCBeatDec 15, 2023
Summarized from public sources; check the original articles before acting on it.
ENDATA